Sanofi just made its largest investment thus far in China. The company has committed just over $1 billion to build a new ...

Amgen's new obesity drug, MariTide, shows promise against giants Eli Lilly and Novo Nordisk, but faces tough competition in a ...

High-yield bargain opportunities exist for disciplined, value-focused investors. Read more about the two standout stocks I've ...

Congress has targeted pharmacy benefit managers for more than two years, spurring millions spent to influence debates that ...

"Importantly, although the most commonly considered osteoporotic fractures (hip, vertebral, forearm, humerus, and pelvis) ...

We recently compiled a list of the 10 High Growth Healthcare Stocks to Invest in Now. In this article, we are going to take a ...

A new study shows that the US is still behind in controlling the price of prescription drugs. One doctor explains why America ...

The approval of Yesintek (ustekinumab-kfce), the sixth biosimilar to reference Stelara, will be used to treat patients with ...

Goldman Sachs analysts removed Amgen (AMGN) from the firm’s US Conviction List as part of its monthly update.Don't Miss our Black Friday ...

The approval marks the sixth biosimilar to reference Stelara (ustekinumab), and it will be used to treat several immunology ...

The biotech industry can be volatile even for relatively large companies. Amgen ( AMGN 1.00%), one of the more prominent names in the game, just reminded us all of that fact. On Nov. 26, the company's ...